- Home
- CHRS vs CCRD Comparison
CHRS vs CCRD Comparison
Compare CHRS & CCRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CCRD
- Stock Information
- Founded
- CHRS 2010
- CCRD 1973
- Country
- CHRS United States
- CCRD United States
- Employees
- CHRS N/A
- CCRD N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CCRD
- Sector
- CHRS Health Care
- CCRD
- Exchange
- CHRS Nasdaq
- CCRD Nasdaq
- Market Cap
- CHRS 191.3M
- CCRD 192.4M
- IPO Year
- CHRS 2014
- CCRD N/A
- Fundamental
- Price
- CHRS $1.24
- CCRD $22.06
- Analyst Decision
- CHRS Strong Buy
- CCRD Hold
- Analyst Count
- CHRS 4
- CCRD 1
- Target Price
- CHRS $5.38
- CCRD $15.00
- AVG Volume (30 Days)
- CHRS 2.0M
- CCRD 45.2K
- Earning Date
- CHRS 03-12-2025
- CCRD 02-12-2025
- Dividend Yield
- CHRS N/A
- CCRD N/A
- EPS Growth
- CHRS N/A
- CCRD 6.70
- EPS
- CHRS N/A
- CCRD 0.49
- Revenue
- CHRS $304,340,000.00
- CCRD $54,733,000.00
- Revenue This Year
- CHRS $2.47
- CCRD $1.95
- Revenue Next Year
- CHRS N/A
- CCRD $12.19
- P/E Ratio
- CHRS N/A
- CCRD $46.49
- Revenue Growth
- CHRS 44.19
- CCRD N/A
- 52 Week Low
- CHRS $0.66
- CCRD $10.02
- 52 Week High
- CHRS $2.87
- CCRD $24.97
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- CCRD 48.05
- Support Level
- CHRS $1.38
- CCRD $22.11
- Resistance Level
- CHRS $1.45
- CCRD $23.88
- Average True Range (ATR)
- CHRS 0.13
- CCRD 1.05
- MACD
- CHRS -0.04
- CCRD -0.21
- Stochastic Oscillator
- CHRS 4.50
- CCRD 13.39
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About CCRD CoreCard Corporation
CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.